Abstract
Abstract
Health technology assessment (HTA) agencies are considering adopting a lifecycle approach to assessments to address uncertainties in the evidence base at launch and to revisit the clinical and economic value of therapies in a dynamic clinical landscape. For reassessments of therapies post launch, HTA agencies are looking to real-world evidence (RWE) to enhance the clinical and economic evidence base, though challenges and concerns in using RWE in decision-making exists. Stakeholders are embarking on demonstration projects to address the challenges and concerns and to further define when and how RWE can be used in HTA decision making. The Institute for Clinical and Economic Review piloted a 24-month observational RWE reassessment. Key learnings from this pilot include identifying the benefits and challenges with using RWE in reassessments and considerations on prioritizing and selecting topics relevant for RWE updates.
Funder
Institute for Clinical and Economic Review
Publisher
Cambridge University Press (CUP)
Reference34 articles.
1. Organized structure of real-world evidence best practices: Moving from fragmented recommendations to comprehensive guidance;Jaksa;J Comp Eff Res.,2021
2. Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study;van Onzenoort;Hypertens Dallas Tex 1979,2011
3. Use of health care databases to support supplemental indications of approved medications;Fralick;JAMA Intern Med.,2018
4. How to Deal with the Inevitable: Generating Real-World Data and Using Real-World Evidence for HTA Purposes – From Theory to Action
5. Are value assessment frameworks using RWE? A review of NICE and ICER psoriasis assessments;Jaksa;Int Soc Pharmacoeconomics Outcomes Res,2019
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献